Can Alnylam Pharmaceuticals Stock Recover If Markets Fall?
Alnylam Pharmaceuticals (ALNY) stock is down 11.3% in 5 trading days. The recent slide reflects renewed concerns around insider selling and widening net losses, but sharp drops like this often raise a tougher question: is the weakness temporary, or a sign of deeper cracks in the story?
Before judging its downturn reslience, let’s look at where Alnylam Pharmaceuticals stands today.
- Size: Alnylam Pharmaceuticals is a $54 Bil company with $3.2 Bil in revenue currently trading at $412.63.
- Fundamentals: Last 12 month revenue growth of 53.2% and operating margin of 8.2%.
- Liquidity: Has Debt to Equity ratio of 0.02 and Cash to Assets ratio of 0.56
- Valuation: Alnylam Pharmaceuticals stock is currently trading at P/E multiple of 1375.9 and P/EBIT multiple of 460.0
- Has returned (median) -0.9% within a year following sharp dips since 2010. See ALNY Dip Buy Analysis.
These metrics point to a Strong operational performance, alongside Very High valuation – making the stock Relatively Expensive. For details, see Buy or Sell ALNY Stock
That brings us to the key consideration for investors worried about this fall: how resilient is ALNY stock if markets turn south? This is where our downturn resilience framework comes in. Suppose ALNY stock falls another 20-30% to $289 – can investors comfortably hold on? Turns out, the stock saw an impact slightly worse than the S&P 500 index during various economic downturns, based on (a) how much the stock fell and, (b) how quickly it recovered. Below, we dive deeper into each such downturn.
2022 Inflation Shock
- ALNY stock fell 42.5% from a high of $209.29 on 14 October 2021 to $120.42 on 11 May 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 3 August 2022
- Since then, the stock increased to a high of $491.22 on 20 October 2025 , and currently trades at $412.63
| ALNY | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -42.5% | -25.4% |
| Time to Full Recovery | 84 days | 464 days |
2020 Covid Pandemic
- ALNY stock fell 30.5% from a high of $133.99 on 12 February 2020 to $93.12 on 12 March 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 17 April 2020
| ALNY | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -30.5% | -33.9% |
| Time to Full Recovery | 36 days | 148 days |
2018 Correction
- ALNY stock fell 57.8% from a high of $148.54 on 20 March 2018 to $62.67 on 24 December 2018 vs. a peak-to-trough decline of 19.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 19 June 2020
| ALNY | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -57.8% | -19.8% |
| Time to Full Recovery | 543 days | 120 days |
2008 Global Financial Crisis
- ALNY stock fell 58.6% from a high of $36.55 on 9 October 2007 to $15.14 on 9 March 2009 vs. a peak-to-trough decline of 56.8% for the S&P 500.
- However, the stock fully recovered to its pre-Crisis peak by 3 July 2013
| ALNY | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -58.6% | -56.8% |
| Time to Full Recovery | 1577 days | 1480 days |
Feeling jittery about ALNY stock? Consider portfolio approach.
Portfolios Beat Stock Picking
Stocks soar and sink – the key is staying invested. A balanced portfolio keeps you in the market, boosts gains and reduces single stock risk
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.